Consistently with these findings, AXL genetic or pharmacological inhibition in ovarian cancer led to impaired migration and metastasis and in increased chemo-sensitivity of both patient derived xenograft and ovarian cell lines [24, 26] and could therefore represent a promising therapeutic target in EOC. The gene discussed is AXL; the disease is ovarian cancer.